Table 1.
Clinical and pathological characteristics of the study population.
| Characteristic | Total population (n = 64) |
|---|---|
| Age in years, median (IQR) | 84 (80–94) |
| Cancer stage, no. (%) | |
| IA | 35 (54.7) |
| IB | 29 (45.3) |
| Histologic grade, no. (%) | |
| 1 | 6 (9.4) |
| 2 | 46 (71.9) |
| 3 | 12 (18.7) |
| Lymphovascular invasion (LVSI), no. (%) | |
| Absent | 45 (70.3) |
| Present | 15 (23.4) |
| Indeterminate/unknown | 4 (6.3) |
| Cancer risk stratification, no. (%) | |
| Low intermediate | 13 (20.3) |
| High intermediate | 51 (79.7) |
| Hysterectomy approach, no. (%) | |
| Open | 23 (35.9) |
| Laparoscopic | 12 (18.8) |
| Robotic | 27 (42.2) |
| Vaginal | 2 (3.1) |
| Lymph node dissection, no. (%) | |
| No | 12 (18.8) |
| Pelvic | 14 (21.9) |
| Pelvic and periaortic | 38 (59.4) |
| EBL, no. (%) | |
| < Median (90 mL) | 31 (48.4) |
| ≥ Median |
33 (51.6) |
| Adjuvant therapy, no. (%) | |
| No | 20 (31.2) |
| Radiation alone | 43 (67.2) |
| Chemoradiation | 1 (1.6) |
| Recurrence, no. (%) | |
| Yes | 7 (10.9) |
| No | 57 (89.1) |
| Death, no. (%) | |
| Yes | 26 (40.6) |
| No | 38 (59.4) |
| Cause of death, no. (%) | |
| Disease recurrence | 2 (7.7) |
| Comorbidities | 24 (92.3) |
| Postoperative morbidity*, no. (%) | |
| Infectious morbidity | 16 (25) |
| Pneumonia | 6 (9.4) |
| Cellulitis | 3 (4.7) |
| Urinary tract infection | 5 (7.8) |
| Fever of unknown origin | 2 (3.1) |
| Postoperative transfusion | 2 (3.1) |
| Step-down unit admission | 3 (4.7) |
| Intensive care unit admission | 3 (4.7) |
| Readmission | 3 (4.7) |
| Length of stay, no. (%) | |
| ≤ Median (2 days) | 35 (54.7) |
| > Median | 29 (45.3) |
| CA-CCI score, no. (%) | |
| < Median (7) | 29 (45.3) |
| ≥ Median |
35 (54.7) |
*Not mutually exclusive. EBL, estimated blood loss; CA-CCI, combined age-Charlson comorbidity index.